The CHMP plays a vital role in the authorisation of medicines in the European Union (EU).
In the centralised procedure, the CHMP is responsible for:
The CHMP also evaluates medicines authorised at national level referred to EMA for a harmonised position across the EU. For more information, see Referral procedures.
Access to safe and effective medication is crucial to protect the health of millions of people in the European Union
In addition, the CHMP and its working parties contribute to the development of medicines and medicine regulation, by:
The CHMP's assessments are based on a comprehensive scientific evaluation of data. They determine whether the medicine meets the necessary quality, safety and efficacy requirements and that it has a positive risk-benefit balance. An internal peer-review system safeguards the accuracy and validity of the opinions of the committee. The CHMP replaced the former Committee for Proprietary Medicinal Products (CPMP) in May 2004.
For full details, see the CHMP rules of procedure and work plan.
EMA's Committee for Medicinal Products for Human Use (CHMP) meets once a month. EMA publishes the agendas, minutes and highlights of the plenary meetings. EMA also publishes the agendas and minutes of the CHMP's preparatory and organisational matters (PROM) meeting, formerly known as the CHMP's organisational matters (ORGAM) meeting.
The PROM is a meeting to discuss CHMP organisational matters and other topics in preparation for the CHMP plenary meeting. Its name changed from ORGAM to PROM in February 2021.
The Committee has been publishing meeting reports summarising the main outcomes of its meetings since it was established.
Before start of Committee plenary.
EMA publishes the CHMP agendas since its December 2013 meeting.
After Committee plenary where minutes are adopted.
EMA publishes the CHMP agendas and minutes since its December 2013 meeting
Friday after Committee plenary.
The web-based format of the CHMP meeting highlights replaced the PDF format of the CHMP press releases and monthly report in September 2011.
Week before Committee plenary.
As of June 2023, CHMP no longer publishes the PROM meeting agendas. You can find information on the agenda discussed in the PROM meeting minutes.
After current month's Committee plenary.
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.
EMA has recommended granting a marketing authorisation in the European Union (EU) for Fabhalta (iptacopan), an oral treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its March 2024 meeting.
EMA has recommended granting a marketing authorisation in the European Union (EU) for Emblaveo (aztreonam-avibactam), indicated for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections caused by certain types of bacteria (aerobic Gram-negative) where treatment options are limited.
EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting.
EMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.